Non-promotional in-service PADCEV ® (Enfortumab Vedotin) Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: The phase 3 EV-303 study.
Presenter:Jason Cohen, PhDMedical Science Liaison – GU OncologyMedical Affairs, Americas | Astellas Pharma, Inc
Where:Ruth’s Chris Steak House20 Second Avenue SouthwestRochester, MN 55902
When:Tuesday, January 135:30 pm – 7:00 pm
Please RSVP to Mark Hublymark.hubly@astellas.com(507) 261-4399